14.03.2021, 2527 Zeichen

Valneva: Valneva, a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress into pivotal Phase 3 studies. As announced in December 2020, VLA15-221 is a randomized, observer-blind, placebo-controlled Phase 2 study. It will be the first VLA15 study to include a pediatric population (aged 5-17 years). Overall, the study will enroll approximately 600 healthy participants (aged 5-65 years) who will receive VLA15 or placebo. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). Juan Carlos Jaramillo, Chief Medical Officer of Valneva commented, “This trial initiation marks an important step in the development of VLA15 toward a potential licensure. Including a pediatric population in Phase 2 means we could, if successful, add this population to the Phase 3 research program, to potentially offer a vaccine for Lyme disease that may help prevent disease in both adults and children, if approved. We are pleased that, together with our partner Pfizer, we have decided to pursue this development while preparing for a potential Phase 3 start.”
Valneva: weekly performance: -0.59%

RHI Magnesita: RHI Magnesitam global supplier of refractory products, systems and solutions, announced the Company’s Full Year Results for 2020. Revenues decreased by 23 % to Euro 2,259 mn, adjusted EBITA went down by 36 % to 260 mn. The Company achieved a positive adjusted operating cash flow of Euro 290 mn (2019: Euro 359 mn), supported by strong working capital management leading to a reduction in net debt to Euro 582 mn (2019: Euro 650 mn). The Board has recommended a final dividend of Euro 1.00 per share, bringing the total dividend in respect of 2020 to Euro 1.50 per share. The Company said that it is stepping up efforts to achieve its aspiration to become CO₂ neutral. For this matter, the Group introduces a major four-year R&D program designed to expand its leading sustainability position within the refractories industry. RHI Magnesita will invest Euro 50 mn towards technology research and pilot plant constructions in the next four years, including new technology for the capture of CO₂.
RHI Magnesita: weekly performance: 1.69%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (08/03/2021)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 25/365: Dominik Hojas heute als Voice für Bildung in mehrerlei Hinsicht

Bildnachweis

Aktien auf dem Radar:EuroTeleSites AG, Rosenbauer, Porr, Austriacard Holdings AG, AT&S, Lenzing, Uniqa, Pierer Mobility, FACC, DO&CO, Zumtobel, Josef Manner & Comp. AG, Warimpex, UBM, RHI Magnesita, SW Umwelttechnik, Flughafen Wien, Oberbank AG Stamm, Addiko Bank, Agrana, Amag, EVN, OMV, Österreichische Post, Telekom Austria, VIG, Wienerberger, MTU Aero Engines, HeidelbergCement, SAP, Siemens Energy.

---